SCHEMBL6791489

SCHEMBL6791489

CN(C)C(=O)[C@H]1CCCNC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.59
SLC6A11 P48066 1/20 0.59
TSHR P16473 1/20 0.59
LMNA P02545 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
SLC6A13 Q9NSD5 1/20 0.59
KDM4E B2RXH2 1/20 0.57
MAPT P10636 1/20 0.57
KMT2A Q03164 1/20 0.57
ATM Q13315 1/20 0.57
CYP2D6 P10635 1/20 0.57
GLI1 P08151 1/20 0.47
NOS2 P35228 1/20 0.47
CDK9 P50750 1/20 0.40
DPP4 P27487 2/20 0.39
REN P00797 1/20 0.37
BCHE P06276 1/20 0.36
CPN1 P15169 2/20 0.35
CPB2 Q96IY4 2/20 0.35
APLNR P35414 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716055 1.00 SLC6A1 (0.59) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL16584230 1.00 SLC6A1 (0.59) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL16584210 0.98 SLC6A1 (0.57) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL16584212 0.98 SLC6A1 (0.57) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL6195102 0.98 SLC6A1 (0.57) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL31739419 0.94 SLC6A1 (0.52) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
Trifluoroacetic Acid SCHEMBL5908361 0.88 SLC6A1 (0.51) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL2148728 0.88 GABRA5 (0.43) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL2146012 0.88 GABRA5 (0.43) SLC6A1SLC6A11TSHRLMNASMN1; SMN2
SCHEMBL2672481 0.88 GABRA5 (0.43) SLC6A1SLC6A11TSHRLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039206-A1 Process for resolving racemic mixtures of piperidine derivatives MOHER ERIC DAVID (US) 2004-02-26 US disclosed
US-6664271-B1 Amide, carbamate and uredo derivatives of 3-piperidine-carboxylic acid or ester; protecting against infection by such as escherichia coli and/or actinobacillus pleuropneumoniae ELI LILLY AND COMPANY 2003-12-16 US disclosed
EP-1341762-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES OF PIPERIDINE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-09-10 EP disclosed
WO-2002068391-A1 PROCESS FOR RESOLVING RACEMIC MIXTURES OF PIPERIDINE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039206-A1 Process for resolving racemic mixtures of piperidine derivatives SRR, OPRM1, SRM SLC6A1 545/4885SLC6A11 427/4885TSHR 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.